{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:48:41Z","timestamp":1787240921927,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to explore the effects of teriparatide (TPTD) on treatment duration, surgical procedures, and bone turnover markers in medication-related osteonecrosis of the jaw (MRONJ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 76 patients with MRONJ post-treatment and divided them into conservative\/surgical and TPTD\/non-TPTD groups. Key assessments included treatment duration, surgery count, and changes in bone markers (serum C-terminal telopeptide of type 1 collagen [CTX], osteocalcin [OC], procollagen type 1\u00a0N-terminal propeptide [P1NP], parathyroid hormone [PTH], 25-OH-vitamin D [25(OH)D], calcium, and inorganic phosphorus) measured at the initial and post-treatment stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TPTD-treated surgical patients experienced shorter treatment periods and underwent fewer surgeries than did non-TPTD counterparts. Post-treatment, both groups showed significant increases in CTX, OC, and 25(OH)D levels. P1NP elevation was significant only in the non-TPTD group. Although the PTH levels decreased in both groups, the difference was not statistically significant. Calcium and phosphorus levels increased in both groups, but only calcium levels increased significantly in the TPTD group. Additionally, TPTD-treated patients showed significant improvements in T-scores, particularly in the lumbar spine and femur neck, compared to the non-TPTD group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TPTD administration during MRONJ treatment potentially reduces the need for surgical intervention and accelerates recovery, significantly affecting bone metabolism. These findings highlight TPTD\u2019s role in enhancing the efficacy of MRONJ treatment. TPTD could potentially offer the dual benefit of promoting bone healing and reducing the need for surgical intervention, thus improving overall outcomes for patients with MRONJ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12903-025-05867-w","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T02:00:38Z","timestamp":1744336838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment period and changes in bone markers according to the application of teriparatide in treating medication-related osteonecrosis of the jaw"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-9554","authenticated-orcid":false,"given":"Jin Hoo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-1156","authenticated-orcid":false,"given":"Wonse","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9369-5102","authenticated-orcid":false,"given":"Loi Phuoc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1672-5730","authenticated-orcid":false,"given":"Jin-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7948-7419","authenticated-orcid":false,"given":"Sanghuem","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-0834","authenticated-orcid":false,"given":"Hyunmi","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-4004","authenticated-orcid":false,"given":"Hyung Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-6508","authenticated-orcid":false,"given":"Young-Soo","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-6135","authenticated-orcid":false,"given":"Jun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"2","key":"5867_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","volume":"61","author":"S Kuroshima","year":"2019","unstructured":"Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review. J Oral Biosci. 2019;61(2):99\u2013104.","journal-title":"J Oral Biosci"},{"issue":"5","key":"5867_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26(5):688\u2013703.","journal-title":"Endocr Rev"},{"issue":"9","key":"5867_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxil Surg. 2003;61(9):1115\u20137.","journal-title":"J Oral Maxil Surg"},{"issue":"5","key":"5867_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American association of oral and maxillofacial surgeons\u2019 position paper on Medication-Related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg. 2022;80(5):920\u201343.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"5867_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-019-0160-3","volume":"10","author":"M Salgueiro","year":"2019","unstructured":"Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J. 2019;10(1):21\u20139.","journal-title":"EPMA J"},{"issue":"8","key":"5867_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.adaj.2017.04.002","volume":"148","author":"M El-Rabbany","year":"2017","unstructured":"El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Am Dent Assoc. 2017;148(8):584\u2013e594582.","journal-title":"J Am Dent Assoc"},{"issue":"26","key":"5867_CR7","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.19.02192","volume":"38","author":"IW Sim","year":"2020","unstructured":"Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Papatziamos Hjelle C, Siddique M, Cook GJR, Seymour JF, Ebeling PR. Teriparatide promotes bone healing in Medication-Related osteonecrosis of the jaw: A Placebo-Controlled, randomized trial. J Clin Oncol. 2020;38(26):2971\u201380.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5867_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijom.2020.07.021","volume":"50","author":"M Anabtawi","year":"2021","unstructured":"Anabtawi M, Tweedale H, Mahmood H. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2021;50(4):501\u201310.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"3","key":"5867_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","volume":"65","author":"RP Harper","year":"2007","unstructured":"Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1\u201334)]. J Oral Maxillofac Surg. 2007;65(3):573\u201380.","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"5867_CR10","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.ijom.2013.05.001","volume":"42","author":"EH Dayisoylu","year":"2013","unstructured":"Dayisoylu EH, Senel FC, Ungor C, Tosun E, Cankaya M, Ersoz S, Taskesen F. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. Int J Oral Maxillofac Surg. 2013;42(11):1475\u201380.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"8","key":"5867_CR11","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/clinchem\/47.8.1347","volume":"47","author":"M Kleerekoper","year":"2001","unstructured":"Kleerekoper M. Biochemical markers of bone turnover: why theory, research, and clinical practice are still in conflict. Clin Chem. 2001;47(8):1347\u20139.","journal-title":"Clin Chem"},{"issue":"6","key":"5867_CR12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.joms.2008.02.003","volume":"66","author":"RE Marx","year":"2008","unstructured":"Marx RE. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment - In reply. J Oral Maxil Surg. 2008;66(6):1321\u20132.","journal-title":"J Oral Maxil Surg"},{"issue":"5","key":"5867_CR13","first-page":"417","volume":"73","author":"DK Lam","year":"2007","unstructured":"Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007;73(5):417\u201322.","journal-title":"J Can Dent Assoc"},{"issue":"9","key":"5867_CR14","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","volume":"68","author":"TS Lazarovici","year":"2010","unstructured":"Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, Yahalom R, Taicher S, Yarom N. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg. 2010;68(9):2241\u20137.","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"5867_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jos.2020.01.012","volume":"25","author":"K Morishita","year":"2020","unstructured":"Morishita K, Yamada SI, Kawakita A, Hashidume M, Tachibana A, Takeuchi N, Ohbayashi Y, Kanno T, Yoshiga D, Narai T, et al. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan. J Orthop Sci. 2020;25(6):1079\u201383.","journal-title":"J Orthop Sci"},{"issue":"3","key":"5867_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00198-019-05199-w","volume":"31","author":"Y Ohbayashi","year":"2020","unstructured":"Ohbayashi Y, Iwasaki A, Nakai F, Mashiba T, Miyake M. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporos Int. 2020;31(3):577\u201385.","journal-title":"Osteoporos Int"},{"issue":"4","key":"5867_CR17","first-page":"367","volume":"124","author":"JM Bugueno","year":"2017","unstructured":"Bugueno JM, Migliorati CA. AAOM clinical practice statement subject: the use of serum C-terminal telopeptide cross-link of type 1 collagen (CTX) testing in predicting risk of osteonecrosis of the jaw (ONJ). Or Surg or Med or Pa. 2017;124(4):367\u20138.","journal-title":"Or Surg or Med or Pa"},{"issue":"4","key":"5867_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5125\/jkaoms.2018.44.4.174","volume":"44","author":"WJ Shin","year":"2018","unstructured":"Shin WJ, Kim CH. Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg. 2018;44(4):174\u201381.","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"issue":"4","key":"5867_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.11005\/jbm.2015.22.4.151","volume":"22","author":"KM Kim","year":"2015","unstructured":"Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean society for bone and mineral research and the Korean association of oral and maxillofacial surgeons. J Bone Metab. 2015;22(4):151\u201365.","journal-title":"J Bone Metab"},{"issue":"10","key":"5867_CR20","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/jbmr.3191","volume":"32","author":"S Hayashida","year":"2017","unstructured":"Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, Shibuya Y, Ueda N, et al. Evaluation of the treatment strategies for Medication-Related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis. J Bone Min Res. 2017;32(10):2022\u20139.","journal-title":"J Bone Min Res"},{"issue":"11","key":"5867_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.oraloncology.2014.08.016","volume":"50","author":"K Rupel","year":"2014","unstructured":"Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, Di Lenarda R, Biasotto M. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049\u201357.","journal-title":"Oral Oncol"},{"issue":"12","key":"5867_CR22","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.joms.2007.10.002","volume":"65","author":"LA Assael","year":"2007","unstructured":"Assael LA. Serum CTX to prevent osteonecrosis\/orthodontic extraction of third molars: paths toward minimizing surgical risk? J Oral Maxillofac Surg. 2007;65(12):2395\u20136.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"5867_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/ID.0b013e3181cec8bc","volume":"19","author":"CYS Lee","year":"2010","unstructured":"Lee CYS, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of Bisphosphonate-Associated osteonecrosis of the jaws after surgery?? Part II: A prospective clinical study. Implant Dent. 2010;19(1):29\u201338.","journal-title":"Implant Dent"},{"key":"5867_CR24","doi-asserted-by":"crossref","unstructured":"Boffano P, Agnone AM, Neirotti F, Bonfiglio R, Brucoli M, Ruslin M, Durkovi\u0107 A, Milosavljevi\u0107 M, Konstantinovic V, Rodr\u00edguez JCV et al. Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study. J Stomatology Oral Maxillofacial Surg 2024:101931.","DOI":"10.1016\/j.jormas.2024.101931"},{"issue":"9","key":"5867_CR25","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.3390\/jcm12093299","volume":"12","author":"M Dioguardi","year":"2023","unstructured":"Dioguardi M, Spirito F, Alovisi M, Aiuto R, Garcovich D, Crincoli V, Ballini A, Caloro GA, Lo Muzio L. Location and gender differences in osteonecrosis of the jaws in patients treated with antiresorptive and antineoplastic drugs undergoing Dentoalveolar surgical, systematic review with Meta-Analysis and trial sequential analysis. J Clin Med. 2023;12(9):3299.","journal-title":"J Clin Med"},{"issue":"3","key":"5867_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11926-009-0023-3","volume":"11","author":"E File","year":"2009","unstructured":"File E, Deal C. Clinical update on teriparatide. Curr Rheumatol Rep. 2009;11(3):169\u201376.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"5867_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ajoms.2019.03.001","volume":"31","author":"H Ikeda","year":"2019","unstructured":"Ikeda H, Yoshiga D, Kokabu S, Ariyoshi W, Tsurushima H, Sakaguchi O, Tanaka J, Kaneko J, Habu M, Sasaguri M, et al. Evaluation of therapeutic effects of teriparatide in a rat model of Zoledronic acid-induced bisphosphonate-related osteonecrosis. J Oral Maxillofacial Surg Med Pathol. 2019;31(5):333\u201341.","journal-title":"J Oral Maxillofacial Surg Med Pathol"},{"issue":"3","key":"5867_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/odi.13275","volume":"26","author":"W Yu","year":"2020","unstructured":"Yu W, Su J. The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice. Oral Dis. 2020;26(3):609\u201320.","journal-title":"Oral Dis"},{"issue":"5","key":"5867_CR29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00198-014-2622-8","volume":"25","author":"KM Kim","year":"2014","unstructured":"Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, Rhee Y, Cha IH. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int. 2014;25(5):1625\u201332.","journal-title":"Osteoporos Int"},{"issue":"11","key":"5867_CR30","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00198-011-1882-9","volume":"23","author":"YD Kwon","year":"2012","unstructured":"Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int. 2012;23(11):2721\u20135.","journal-title":"Osteoporos Int"},{"issue":"2","key":"5867_CR31","first-page":"222","volume":"24","author":"RM Doh","year":"2015","unstructured":"Doh RM, Park HJ, Rhee Y, Kim HS, Huh J, Park W. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants. Implant Dent. 2015;24(2):222\u20136.","journal-title":"Implant Dent"},{"issue":"4","key":"5867_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/dj4040041","volume":"4","author":"Y-D Kwon","year":"2016","unstructured":"Kwon Y-D, Kim D-Y. Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ). Dentistry J. 2016;4(4):41.","journal-title":"Dentistry J"},{"key":"5867_CR33","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","volume":"19","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Westfall A, Cheng H, Delzell E, Saag K. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008;19:1613\u201320.","journal-title":"Osteoporos Int"},{"key":"5867_CR34","doi-asserted-by":"crossref","unstructured":"Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res 2017, 5.","DOI":"10.1186\/s40364-017-0097-4"},{"issue":"4","key":"5867_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00774-020-01099-w","volume":"38","author":"J Takada","year":"2020","unstructured":"Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to Romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial (17, Pg 451, 2020). J Bone Min Metab. 2020;38(4):605\u2013605.","journal-title":"J Bone Min Metab"},{"issue":"12","key":"5867_CR36","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/jbmr.3237","volume":"32","author":"J Jung","year":"2017","unstructured":"Jung J, Yoo HY, Kim GT, Lee JW, Lee YA, Kim DY, Kwon YD. Short-Term teriparatide and Recombinant human bone morphogenetic Protein-2 for regenerative approach to Medication-Related osteonecrosis of the jaw: A preliminary study. J Bone Min Res. 2017;32(12):2445\u201352.","journal-title":"J Bone Min Res"},{"issue":"9","key":"5867_CR37","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00198-014-2646-0","volume":"25","author":"JH Krege","year":"2014","unstructured":"Krege JH, Lane NE, Harris JM, Miller PD. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014;25(9):2159\u201371.","journal-title":"Osteoporos Int"},{"issue":"6","key":"5867_CR38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/jbmr.23","volume":"25","author":"A Hokugo","year":"2010","unstructured":"Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, Garrett N, Adams JS, Nishimura I. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Min Res. 2010;25(6):1337\u201349.","journal-title":"J Bone Min Res"},{"issue":"6","key":"5867_CR39","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bone.2012.02.635","volume":"50","author":"F Cosman","year":"2012","unstructured":"Cosman F, Dawson-Hughes B, Wan XH, Krege JH. Changes in vitamin D metabolites during teriparatide treatment. Bone. 2012;50(6):1368\u201371.","journal-title":"Bone"},{"issue":"20","key":"5867_CR40","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1001\/archinte.162.20.2297","volume":"162","author":"C Crandall","year":"2002","unstructured":"Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med. 2002;162(20):2297\u2013309.","journal-title":"Arch Intern Med"},{"issue":"3","key":"5867_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1620\/tjem.242.241","volume":"242","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Uchiyama S, Kamimura M, Ikegami S, Komatsu M, Kato H. Increased serum 25(OH)D levels in Post-Menopausal Japanese women with osteoporosis after 3-Year bisphosphonate treatment. Tohoku J Exp Med. 2017;242(3):241\u20136.","journal-title":"Tohoku J Exp Med"},{"issue":"12","key":"5867_CR42","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.jcms.2017.09.015","volume":"45","author":"N Heim","year":"2017","unstructured":"Heim N, Warwas FB, Wilms CT, Reich RH, Martini M. Vitamin D (25-OHD) deficiency May increase the prevalence of medication-related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2017;45(12):2068\u201374.","journal-title":"J Craniomaxillofac Surg"},{"key":"5867_CR43","first-page":"802473","volume":"2014","author":"N Thiruchelvam","year":"2014","unstructured":"Thiruchelvam N, Randhawa J, Sadiek H, Kistangari G. Teriparatide induced delayed persistent hypercalcemia. Case Rep Endocrinol. 2014;2014:802473.","journal-title":"Case Rep Endocrinol"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-05867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-025-05867-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-05867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:16:16Z","timestamp":1744344976000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-025-05867-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5867"],"URL":"https:\/\/doi.org\/10.1186\/s12903-025-05867-w","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Research Ethics Committee of Yonsei University College of Dentistry (IRB No. 2-2021-0017). The need for informed consent was waived as this study is a retrospective analysis of medical records and was deemed unnecessary according to national regulations, specifically Article 18 of the Bioethics and Safety Act of South Korea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"528"}}